Abstract: Objective The aim of this study was to investigate the short-term efficacy of tenofovir dipivoxil and entecavir in treating patients with chronic hepatitis B (CHB) and serum fibroblast growth factor-23 (FGF-23) level changes.Methods 150 patients with CHB were recruited in our hospital between January 2018 and January 2019, and were divided into two groups, with 75 in each, receiving entecavir or tenofovir for 48 weeks. Serum cytokine levels in the two groups before and after 48 weeks of treatment were detected by ELISA.Results At the end of 48-week treatment, serum HBV DNA loss in the tenofovir-treated group was 100.0 %, which was significantly higher than 93.3% (P<0.05) in the entecavir-treated group, However, there were no statistical significant differences as respect to serum HBeAg negative or serum alanine aminotransferase normalization between the two groups (10.1% vs. 8.0% and 96.0% vs. 93.3%, respectively, P>0.05); serum HBV DNA level in tenofovir-treated group was(0.9 ± 0.5)Ig IU/mL, not significantly different compared to(1.3 ± 0.6)Ig IU/mL in entecavir-treated group (P>0.05), and there were no significant differences with respect to serum ALT and AST levels between the two groups (P>0.05); serum β2-microglobulin, FGF-23 and cystatin-C levels in tenofovir-treated group were(1.6 ± 0.5)mg/L, (382.2 ± 61.3)pg/mL and (3.0 ± 0.8)mg/L, all significantly higher than 【(1.4 ± 0.5)mg/L,(363.2 ± 53.3)pg/mL and(2.8 ± 0.8)mg/L, respectively, P<0.05】 in the entecavir-treated group.Conclusion The oral administration of entecavir or tenofovir disoproxil in the treatment of patients with CHB could obtain short-term response as serum HBV DNA loss and serum ALT normalization, while the implication of elevated serum β2-MG, FGF-23 and Cys-C levels needs further investigation.

Key words: Hepatitis B, Tenofovir disoproxil, Entecavir, Fibroblast growth factor-23, Therapy